European Union animal testing reg
This article was originally published in The Rose Sheet
Executive Summary
Commission Chemicals Policy White Paper is inconsistent with Parliament's position on animal testing in the Seventh Amendment to the cosmetics directive, European Cosmetic, Toiletry and Perfumery Association maintains in an Oct. 15 statement. "The principal of animal testing where indispensable is recognized in the White Paper on Chemicals: continuing to discriminate against the cosmetics industry on this point is not coherent," Colipa says, noting the cosmetics industry uses chemical ingredients. "Furthermore, it means concentrating on only .3% of the problem," Colipa adds. Chemicals Policy proposes safety assessments for roughly 100,000 chemical substances, which could necessitate animal testing, a measure that is banned under the proposed seventh amendment. The White Paper, which was adopted at the EU committee level Oct. 16, is scheduled for debate before full Parliament Nov. 14...
You may also be interested in...
EU chemical white paper moves forward
European Parliament approves Commission White Paper on Strategy for a Future Chemicals Policy Nov. 15, paving the way for future legislation proposal to be developed in 2002, Parliament announces. Draft text should be finalized in late December, according to Rapporteur Inger Schörling's office. Paper, which calls for "better public information on all chemicals," would require comprehensive minimum data requirements for as many as 100,000 chemicals, including some used in cosmetics. Proposed safety assessments could necessitate animal testing, an allowance the European Cosmetic, Toiletry and Perfumery Association criticized as inconsistent and discriminatory in an Oct. 15 statement (1"The Rose Sheet" Nov. 12, In Brief)...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.